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Background: Acquisition of the M1 or M2 phenotypes by microglia has been shown to occur during the
development of pathological conditions, with M1 activation being widely involved in neurotoxicity in relation with
the anatomical localization and the reactivity of subtypes of microglia cells. On the contrary, little is known on the
ability of microglia to undergo M2 polarization by interleukin-4 (IL4), the typical M2a polarization signal for peripheral
macrophages.
Methods: Recombinant mouse IL4 was injected in the third cerebral ventricle of mice to induce brain alternative
polarization. The mRNA levels of Fizz1, Arg1, and Ym1 genes, known to be up-regulated by IL4 in peripheral
macrophages, together with additional polarization markers, were evaluated in the striatum and frontal cortex at
different time intervals after central administration of IL4; in parallel, M2a protein expression was evaluated in tissue
extracts and at the cellular level.
Results: Our results show that the potency and temporal profile of IL4-mediated M2a gene induction vary depending
on the gene analyzed and according to the specific brain area analyzed, with the striatum showing a reduced M2a
response compared with the frontal cortex, as further substantiated by assays of polarization protein levels. Of notice,
Fizz1 mRNA induction reached 100-fold level, underscoring the potency of this specific IL4 signaling pathway in the
brain. In addition, immunochemistry assays demonstrated the localization of the M2 response specifically to microglia
cells and, more interestingly, the existence of a subpopulation of microglia cells amenable to undergoing M2a
polarization in the healthy mouse brain.
Conclusions: These results show that the responsiveness of brain macrophages to centrally administered IL4 may vary
depending on the gene and brain area analyzed, and that M2a polarization can be ascribed to a subpopulation of
IL4-responsive microglia cells. The biochemical pathways that enable microglia to undergo M2a activation represent
key aspects for understanding the physiopathology of neuroinflammation and for developing novel therapeutic and
diagnostic agents.
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Microglia are myeloid cells that populate the parenchyma
of the central nervous system (CNS); their physiological
activity includes most of the biological properties that
are typical for peripheral macrophages, although their
developmental origin and anatomical distribution allows
these cells to perform distinctive immune and neuromodu-
latory functions in the CNS. Through their physical and
biochemical interaction with neurons, microglia are able to
sense and remodel neuronal activity, support neurogenesis,
and maintain CNS homeostasis [1].
Microglia also possess the striking ability to rapidly
react to endogenous or exogenous signals with a variety
of physiological responses [2]. Like peripheral macrophages,
microglia are activated by bacterial or viral signals to
acquire a classical ‘M1’ reactive phenotype that defeats
invading pathogens through the activation of a wide range
of reactions, such as the release of reactive oxidizing
species and inflammatory mediators; a large body of
evidence shows that the chronic or unrestrained M1
activation of microglia results in neurotoxicity, as
thoroughly demonstrated by the use of the bacterial
endotoxin lipopolysaccharide in several experimental
settings and in vivo [3-6]. The neurotoxic potential of
microglia M1 activation may vary depending on region-
specific signals, as in the case of dopaminergic neurons of
the nigrostriatal pathway, which strongly influence
the outcome of neuroinflammation through pathogenic
mechanisms that include dopamine metabolism and
oxidative stress [7,8]. Furthermore, the inflammatory
M1 phenotype, similarly to resting activities, has been
recently ascribed to subtypes of microglia that, residing
adjacent to each other within the same brain region, take
on certain tasks and not others [9]. This functional hetero-
geneity among microglia has, so far, been documented by
cell distribution and morphology [10], neural-immune
communication [11-14], and response to neurotransmitters
[15] and lipopolysaccharide [16,17].
Conversely, macrophages and microglia undergo an
alternative ‘M2’ phenotype as a consequence of parasite
invasion and in response to the endogenous immune
signals, interleukin-4 (IL4) and interleukin-13 (IL13), in
order to provide tissue repair and resolution of inflamma-
tion. A more detailed analysis led to the identification of
two distinct alternative activation states, M2a and M2c,
which reflect the actions of IL4 and IL13, on the one hand,
and interleukin-10 (IL10) and TGFβ, on the other hand;
importantly, these responses are associated with specific
panels of regulated genes and a distinct range of effects
[18]. However, only a few reports have addressed the study
of M2 polarization in CNS physiopathology and current
knowledge mainly derives from in vitro or ex vivo studies,
showing the responsiveness of microglia to IL4 and the
subsequent activation of gene expression programs relatedto neuroprotection, tissue remodeling, and angiogenesis
[19]. As a consequence, it is not known whether microglia
are able to sustain alternative activation equally through-
out the CNS or whether heterogeneous subtypes of M2
responder microglia exist within the same anatomical
location. Considering the contribution of the M2 pheno-
type to neuroprotection, it is indeed mandatory to fill this
gap of knowledge and reach a wider view of microglia
reactiveness and its involvement in the pathogenesis
of neurologic diseases, particularly those that show a
region-specific pattern of development together with
microglia activation, such as Parkinson’s disease [20].
Furthermore, the study of microglia M2 phenotype
will provide biochemical details for the identification
of novel pharmacological and diagnostic tools that
target microglia activation processes [9].
The aim of this study was thus to investigate microglia
M2 activation in vivo and evaluate the responsiveness
and functional heterogeneity of microglia to undergo
M2 polarization among and within selected brain areas.
We thus stimulated microglia by central administration
of IL4 in the third cerebral ventricle of the mouse brain.
Interestingly, our data show that the induction of micro-
glial M2a phenotype varies among the two brain areas
analyzed, with M2a gene expression being more potent
in the frontal cortex than in the striatum, and that only
a subpopulation of microglia cells within these areas is
amenable to undergoing an M2a response. Finally, we
show that, among the M2a genes tested, Fizz1 reached
the highest induction levels, underscoring the potency of
this IL4 signaling pathway in the brain.
Methods
Materials
Recombinant mouse IL4 was obtained from PeproTech
(London, UK). Unless otherwise specified, chemicals
were purchased from Merck (Darmstadt, Germany).
Animals
C57BL/6− male mice 4 months of age were supplied by
Charles River Laboratories (Calco, Italy). All animals
were allowed free access to food and water and were
kept in temperature-controlled facilities on a 12-hour
light and dark cycle. Animals were housed in the animal
care facility of the Department of Pharmacological and
Biomolecular Sciences at the University of Milan, and
experiments were performed in compliance with regula-
tions approved by the Institutional Animal Care and Use
Committee of the University of Milan and in accordance
with European legislation.
Preparation of bone-marrow-derived macrophages
Bone-marrow-derived macrophages were prepared as
previously described [21]. Briefly, bone marrow from the
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Monza, Italy) using a 21 gage needle. Cells were cen-
trifuged at 1200 rpm for 5 min at 10°C, seeded in
tissue culture plates, and grown for 7 days in DMEM
containing 20% endotoxin-free FBS, 30% L929-cell
conditioned media, 1% L-glutamine, 1% penicillin and
streptomycin, and 0.5% Na pyruvate. On the day of
the experiment, cells were treated for 24 h with
20 ng/ml of IL4 and RNA prepared as described.Intracerebroventricular injections
Intracerebroventricular (icv) injections were made as
previously described [17]. Briefly, mice were deeply anes-
thetized with a subcutaneous injection of a mixture of keta-
mine and xylazine (78 and 6 mg/kg, respectively) and
positioned on a specific stand for the surgical operation.
Injections in the third cerebral ventricle (icv) were
performed according to specific stereotaxic coordinates
(bregma, −0.25 mm; lateral, 1 mm; depth, 2.25 mm), as
previously described [17]. Interleukin-4 was injected in
2.5 μl of 0.9% NaCl using a 26S-gage Hamilton Syringe;
100 and 250 ng were injected to assess RNA and protein
levels, respectively. Infusions were made at a rate of 0.1 μl
in 3 s. The needle was kept in place for 30 s after the
injection and then removed slowly. Animals injected with
the same volume of vehicle (0.9% NaCl) alone were used
as controls. The skin incision was closed with a suture
and animals were allowed to recover for 8, 16, 30 or
48 hours before sacrifice by a lethal ketamine and xylazine
solution (150 and 12 mg/kg, respectively). For RNA
quantification, the right striatum and frontal cortex,
contralateral to the injection site, were collected, immedi-
ately frozen on dry ice, and stored at −80°C until
RNA preparation. For immunological assays, the right
hemisphere was processed for immunohistochemistry,
while ipsilateral areas were frozen on dry ice and stored at
−80°C for Western blot analysis.RNA and cDNA preparation
The striatum and frontal cortex were homogenized
using steel beads and tissue Lyser (QIAGEN, Milan,
Italy) at 28 Hz, for three cycles of 20 s followed by 30 s,
on ice and in RLT buffer and total RNA was purified
using RNeasy minikit (QIAGEN) according to the
manufacturer’s instructions including a step with
deoxyribonuclease incubation. One μg RNA was used
for cDNA preparation using 8 U/μl of Moloney murine
leukemia virus reverse transcriptase (Promega, Milan,
Italy) in a final volume of 25 μl; the reaction was
performed at 37°C for 1 h, and the enzyme inactivated at
75°C for 5 min. Control reactions without the addition of
the reverse transcription enzyme were performed
(data not shown).Real time PCR
A 1:16 cDNA dilution was amplified using SYBR
technology. The PCR was carried out in triplicate or
duplicate on a 96-well plate using GoTaq®qPCR Master
Mix technology (Promega) according to the manufacturer’s
protocol using 7900HT fast real time PCR system (Applied
Biosystems, Life Technologies) with the following thermal
profile: 2 min at 95°C; 40 cycles, 15 s at 95°C, 1 min
at 60°C. Gene expression of target genes was assessed
for arginase-1 (arg1; forward primer, 5′-CAGAAGA
ATGGAAGAGTCAG-3′; reverse primer, 5′-CAGA-
TATGCAGGGAGTCACC-3′), chitinase-like 3 (Chi3l3,
or Ym1; forward primer, 5′-GAAGGAGCCACTGA
GGTCTG-3′; reverse primer, 5′-GAGCCACTGAGCC
TTCAAC-3′), Found-in-the inflammatory zone (Fizz1,
or Retnlα; forward primer, 5′-GGAACTTCTTGCCAA
TCCAGC-3′; reverse primer, 5′-AAGCCACAAGCAC
ACCCAGT-3′), IL4 receptor-α (IL4Rα; forward primer,
5′-AACTCGCAGGTTCTGGCTGG-3′; reverse primer,
5′-AAGCCCCGAGTCCTAGGTT-3′), CD206 (forward
primer, 5′-TTCAGCTATTGGACGCGAGG-3′; reverse
primer, 5′-GAATCTGACACCCAGCGGAA-3′), TGFβ
(forward primer, 5′-ACCAACTATTGCTTCAGCTT-
CAGCTCCAC-3′; reverse primer, 5′-GATCCACTTC-
CAACCCAGGTC-3'), IL1β (forward primer, 5′-TGC
CACCTTTTGACAGTGATG-3′; reverse primer, 5′-GCT
GCGAGATTTGAAGCTGG-3′), TNFα (forward primer,
5′-CCTATGTCTCAGCCTCTTCTC-3′; reverse primer
5′-CTCTTGCTTATCCCCTCTTCC-3′), and for the ref-
erence genes 36B4 (forward primer, 5′-GGCGACCTG-
GAAGTCCAACT-3′; reverse primer, 5′-CCATCAGCAC
CACGGCCTTC-3′) and complement component 1qA
(C1qA; forward primer, 5′-GACCACGGAGGCAGGGA
CAC-3′; reverse primer 5′-CTTCCCGTTGGGTGCTC
GGC-3′). The reactions were carried out according to the
manufacturer's protocol using a 7900HT fast real time
PCR system (Applied Biosystems, Inc.), and the data were
analyzed using the 2-ΔΔCt method.
Western blotting
Brain tissues were homogenized using steel beads with a
tissue Lyser (QIAGEN) at 28 Hz, for 3 cycles of 20 s
followed by 30 s, on ice and in a buffer for total cellular
extracts, containing 5 mM MgCl2, 20 mM HEPES
(pH 7.9), 420 mM NaCl, 0.1 mM EDTA, 20% glycerol,
0.1% Triton, 5 mM β-mercaptoethanol, 0.1 mM PMSF,
10 μg/ml aprotinin, and 1 μg/ml leupeptin. The lysates
were frozen on dry ice for 5 min and then thawed at 37°C
for 5 min for three times. The samples were centrifuged at
13,000 rpm at 4°C for 20 min and the supernatants were
collected and stored at −20°C. Protein concentration was
estimated by Bradford protein assay using BSA as stand-
ard. Equal amounts of protein (20 μg) were dissolved in
Laemmli’s sample buffer, boiled for 5 min, and separated
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polyacrylamide for Ym1 and CD206 detection, respectively)
and then transferred overnight at 15 mA into 0.45 μm
Hybond-ECL membrane (GE Healthcare, Milan, Italy).
Membranes were incubated for 1 h with blocking solution
containing 5% (w/v) nonfat milk in Tris-buffered saline
(TBS) and subsequently probed for 1 h at room
temperature with a rabbit anti-mouse YM1 antibody
(1:1000; Stem Cell Technologies, Grenoble, France) in
incubation solution (TBS containing 5% (w/v) nonfat
milk and 0.1% Tween 20. After extensive washing in
TBST (TBS + 0.1% Tween 20), or goat anti-mouse
MMR/CD206 polyclonal antibody (CD206 (1:500,
R&D Systems, Minneapolis, MN, USA). Blots were incu-
bated with horseradish peroxidase-conjugated goat anti-
rabbit IgG (1:2000, for Ym1 detection) or horse anti-goat
IgG (1:2000, for CD206 detection; both from Vector
Laboratories, Peterborough, UK) in incubation solution,
for 1 h at room temperature. After extensive washing in
TBST, immunoreactive bands were visualized using a
chemiluminescence assay detection system according to
the manufacturer’s instructions (Amersham™ ECL™
Western Blotting Analysis System, GE Healthcare). To
ascertain that blots were loaded with equal amounts
of protein lysates, they were also incubated in the
presence of the antibody against β-actin protein
(1:10,000; Sigma-Aldrich Corp., Milan, Italy). Subsequently,
for semiquantitative analyses, the densities of the protein
bands of YM1 (45 kDa), CD206 (175 kDa), and β-actin
(42 kDa) were measured by densitometric scanning of the
membrane with Gel Doc™ XR Imaging Densitometer
(Bio-Rad Lab, Segrate, Italy) and a computer program
(Quantity One® software, Bio-Rad Lab). Western blotting
images were arranged in the final figures using Microsoft
software.
Immunohistochemistry
All immunohistochemical analyses were performed
on animals treated for 16 h with IL4. Right brain
hemispheres were removed and fixed overnight at 4°C by
immersion in 4% formalin solution.
Cryoprotection
Brains were immersed at 4°C in 30% sucrose solution until
they sank, embedded in optimal cutting temperature
compound, and stored at −80°C until analysis. Coronal
sections of brain 20 μm thick were collected using a
cryostat (Microm HM 505E, Walldorf, Germany).
Free-floating sections were washed five times with
TBS + 0.01% Triton and incubated with blocking solution
(TBS + 10% goat serum + 0.4% Triton) for 1 hour at room
temperature. Next, sections were incubated overnight with
the following antibodies, diluted in TBS with 1% goat
serum: rabbit anti-mouse antibody against Ym1 (1:50dilution, Stem Cell Technologies), rat anti-mouse antibody
against macrophage antigen complex-1 Mac-1 (1:200;
Serotec, Puccheim, Germany), mouse anti-mouse antibody
against feminizing locus on X-3 (NeuN; 1:100; Merck),
mouse anti-mouse glial fibrillary acidic protein (GFAP;
1:500; Sigma-Aldrich). Sections were washed five times
with TBS + 0.01% Triton and incubated for 2 h with
secondary antibodies (1:200 AlexaFlour 488 for Mac1,
NeuN, and GFAP; 1:200 AlexaFlour 555 for Ym1;
Molecular Probes, Monza, Italy) at room temperature.
Sections were washed five times with TBS + 0.01%
Triton and then incubated for 15 minutes with
Hoechst stain (Sigma-Aldrich). In parallel, some sections
were tested for antibody specificity by omitting primary or
secondary antibodies. After five washings in TBS + 0.01%
Triton, sections were mounted on slides and observed
using a Zeiss Axioskop microscope equipped with a
digital camera (Carl Zeiss, Thornwood, NY); images
were captured at 40,000× and 63,000× magnification.
Quantification of Ym1-positive microglia cells was
performed by counting the number of cells showing a
red-labeled Ym1 signal and a green-Mac-1 signal;
cells were scored as positive on the basis of nuclear
DAPI staining in close proximity. Four counting fields
of 50 × 50 μm were analyzed in two sections from
three different levels, at least 120 μm apart, of the
striatum and frontal cortex (n = 3).
Paraffin embedding
Brains were trimmed using a brain matrix (Adult Mouse
Brain Slicer Matrix BSMAS005-1, Zivic Instruments,
Pittsburgh, PA, USA) and sections were routinely
processed, paraffin embedded, and sectioned in 4 μm
serial sections. For Iba1 and Arg1 immunohistochemistry,
sections were immunostained with rabbit polyclonal
anti-Iba1 antibody (ionized calcium-binding adapter
molecule-1, 019-19741, Wako Chemicals, Richmond,
VA, USA), and goat polyclonal anti-Arg1 antibody
(sc-18354, Santa Cruz Biotechnology, Heidelberg,
Germany); sections were than incubated with biotinylated
goat anti-rabbit (Iba1) and rabbit anti-goat (Arg1) secondary
antibodies (VC-BA-1000-MM15 and VC-BA-5000-MM15,
Vector Laboratories, Petersborough, UK), labeled by
the avidin-biotin-peroxidase procedure with a com-
mercial immunoperoxidase kit (VECTASTAIN® Elite
ABC-Peroxidase Kit Standard, VC-PK-6100-KI01, Vector
Laboratories). The immunoreaction was visualized with
DAB (Peroxidase DAB Substrate Kit, VC-SK-4100-KI01,
Vector Laboratories) substrate and sections were counter-
stained with Mayer’s hematoxylin (C0302, Diapath, Italy).
Digital image analysis was performed by scoring the number
of Iba1- and Arg1-positive cells (microglia) in three 400×
microscopic fields in the frontal cortex of both vehicle and
IL4 treated mice (n = 3).
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After 16 h of IL4 or vehicle treatment, brains were
dissected and washed in Hank’s Balanced Salt Solution
(HBSS; Life Technologies); after removing the meninges,
cortices from five mice were pooled as a single experi-
mental group. Enzymatic cell dissociation was performed
using Neural Tissue Dissociation Kit P (Miltenyi Biotec,
Bologna, Italy), following a modified version of the
protocol supplied by the manufacturer. Briefly, after
enzymatic digestion with papain, samples were dissoci-
ated mechanically, homogenized, and filtered through a
40-μm cell strainer. After extensive washes in HBSS,
myelin was removed by centrifuging the dissociated
brain cells, which had previously been suspended in
10 ml of cold 0.9 M sucrose solution, at 850 g and 4°C
for 10 min without braking. Floating myelin and the
supernatant were discarded and cells were processed for
microglia magnetic sorting by incubating with CD11b
MicroBeads (diluted 1:10 in PBS + 0.05% BSA; Miltenyi
Biotec) for 15 min at 4°C; after washings, cells were
suspended in 500 μl of PBS + 0.05% BSA and applied
to a magnetic column to purify CD11b+ cells, namely
microglia. Immediately after isolation of microglia,
cells were fixed with 4% paraformaldehyde, extensively
washed with 125 mM glycine in PBS and permeabilized
overnight in PBS containing 0,1% Triton X-100, 5%
normal goat serum, and 2% BSA, at 4°C. Cells were
incubated with rabbit anti-mouse Ym1 antibody (Stem
Cell Technologies) diluted 1:50 in Incubation Solution
(PBS containing 0.1% Triton X-100, 1% normal goat
serum, and 2% BSA) at room temperature for 1 h.
After extensive washes in incubation solution, cells
were incubated with Alexa633-conjugated anti-rabbit
secondary antibody (1:200 in incubation solution; Molecular
Probes) for 1 h at room temperature. Cells were extensively
washed with PBS and then analyzed with a flow cytometry
system (BD FACSCalibur, Becton Dickinson Biosciences,
San Jose, CA, USA). Isotype IgG controls were also
used to evaluate nonspecific signals. Incubations with
FITC-antiCD11b antibody (Miltenyi Biotec) and flow
cytometry analyses were performed separately on dissoci-
ated brain cells as well as on CD11b-immunosorted cells to
calculate recovery and purity; our protocol allowed us to
obtain 80 to 85% recovery of CD11b-positive microglia
cells, that is, 12% of the total brain cells population
after tissue dissociation and myelin removal, with 90
to 95% purity after magnetic immunosorting.
Statistical evaluation
Unless otherwise stated, all values are expressed as mean ±
standard error of the mean (SEM) of n observations. The
results were analyzed by one-way ANOVA followed by a
Bonferroni post-hoc test for multiple comparisons usingGraphPad Prism 5 software [22]. A value of P <0.05 was
considered significant.
Results
Region-specific differences in IL4-induced M2 gene
expression
To evaluate whether microglia populating different brain
regions are able to attain a similar M2 response, we
analyzed M2 gene expression in the frontal cortex and
striatum, in which M2 polarization was shown to occur
under neurodegenerative conditions [23,24]. The mRNA
levels coding for Fizz1, Arg1, and Ym1 genes, known to
be induced by IL4 in peripheral macrophages, were
analyzed in a time course experiment following icv IL4
treatment. As shown in Figure 1A, Fizz1 mRNA levels in
the frontal cortex were significantly elevated following
8 h treatment and further increased after 16 h, while
after more prolonged time intervals the effect of IL4,
although not statistically significant, could still be
observed and remained around 20-fold higher than
vehicle-injected mice 48 h after the injection of IL4.
Analogously, a significant induction of Fizz1 mRNA
levels was observed in the striatum at the earliest time
points analyzed, with a temporal profile of mRNA induc-
tion that is superimposable to that observed in the cortex,
except for the 8 h treatment; interestingly, at this time point
the effect of IL4 is significantly different in the two brain
areas, with the cortex resulting in a significantly higher
gene induction than the striatum. The increased variability
in Fizz1 mRNA levels that is observed in both brain areas
along with treatment duration could probably account for
loss of statistical significance in the IL4 effect observed at
30 and 48 h after injection.
As shown in Figure 1B, the short-term treatments with
IL4 resulted in a significant induction of Arg1 mRNA
levels in the brain; also, for this M2 gene, the IL4 activity
is significantly more pronounced in the frontal cortex
than in the striatum following 16 and 30 h treatment,
although the response after 8 h treatment is statistically
significant only in the striatum; unlike Fizz1 induction,
no difference between vehicle or IL4-treated mice was
observed at the last time point analyzed. Analogously,
the temporal profile of Ym1 induction also supports
diversity in the response to IL4 among the frontal cortex
and striatum. In fact, Ym1 mRNA levels are increased
for up to 30 h in the frontal cortex, although never
reaching statistical significance, while the effect of IL4 is
weaker and faster in the striatum (Figure 1C). Thus,
these data show that central administration of IL4
enables this signal to distribute from cerebral ventricles
to distant brain regions, such as the frontal cortex, and
allows evaluation of the induction profile of selected M2
genes and the estimation of differences in the M2
response in distinct brain areas.
AB
C
Figure 1 (See legend on next page.)
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Figure 1 Time course of IL4-induced M2 gene expression in frontal cortex and striatum. Following the indicated time intervals after
intracerebroventricular injection of saline (Veh) or IL4, the RNA extracted from the frontal cortex (Fr cortex) and striatum was analyzed by real time PCR to
evaluate (A) Fizz1, (B) Arg1, and (C) Ym1 gene expression. Data sets for each gene were calculated using the 2-ddCt method with respect to the mean value
of the 8 h vehicle group. Bars represent mean values ± SEM. * P< 0.05 versus Veh; ** P< 0.01; *** P< 0.0005 versus Veh; ° P< 0.05 versus IL4 8 h; °° P< 0.05
versus IL4 16 h (n= 4 to 6); a P< 0.0005 versus striatum 8 h; b P< 0.05 versus striatum 8 h; bb P< 0.05 versus striatum 16 h.
A
B
Figure 2 Normalization of M2 gene expression using microglial
gene C1qA. At 8 h after intracerebroventricular injection of saline
(Veh, open bars) or IL4 (IL4, black bars), RNAs from the frontal cortex
and striatum were analyzed by Real Time PCR to evaluate Fizz1 (A)
and Ym1 (B) gene expression. ΔCt values are calculated with respect
to either the 36B4 housekeeping gene (versus 36B4) or C1qA
microglia-specific gene (versus C1qA) and are shown as the 2-ddCt
method with respect to the mean value of the vehicle group. Bars
represent mean values ± SEM (n = 4 to 6).
Pepe et al. Journal of Neuroinflammation  (2014) 11:211 Page 7 of 14We next asked whether the different intensity of the IL4
response observed between striatum and frontal cortex
could be ascribed to a difference in the number of microglia
cells that reside in these areas. We calculated M2a gene
expression in relation to the mRNA levels of C1qA, a gene
that is highly expressed specifically in microglia [25] and
that reflects the amount of microglia cells present in whole
extracts of a given brain area; as shown in Figure 2, a
similar potency and temporal profile of IL4 activity is
observed in the striatum and frontal cortex to those shown
in Figure 1, suggesting that the region-specific difference in
IL4 responses cannot be ascribed to a different microglia
cell number within the areas analyzed.
Based on recent knowledge suggesting that microglia
or macrophage activation exists as a spectrum of combi-
nations of activation markers that are strictly dependent
on experimental conditions [26], we evaluated the
expression of additional genes, selectively involved in
M2a, M2c, or M1 activation states [18]. As shown in
Figure 3A, CD206 (Mrc1) mRNA levels are significantly
increased in the frontal cortex following 8 and 16 h
treatment, while no effect is observed after longer treat-
ments. This effect was expected based on the fact that
CD206 is also associated with the M2a phenotype induced
by IL4; however, the induction level of this gene is much
lower than those observed for the M2a genes, reported in
Figure 1. Interestingly, CD206 mRNA induction is
observed in the striatum following 8 h, while IL4 activity
is lost afterwards; this is consistent with a reduced IL4
response of this brain area as compared to the frontal
cortex. The mRNA levels of TGFβ, as an M2c marker, as
well as IL1β and TNFα, which are M1 response genes
associated with inflammation, showed no alteration at any
points of our time course experiment, as shown in
Figure 3. In addition, we did not observe expression of
IL10 mRNA in either vehicle- or IL4-treated mice, sug-
gesting that this gene is not expressed in the brain and is
not responsive to IL4 (data not shown). Thus, these data
show the consistency of the icv IL4 experimental scenario
with an M2a activation state, as that previously associated
with IL4 activity in different macrophage populations; in
addition, these results demonstrate that icv injections of
vehicle or IL4 do not induce a classical inflammatory
response, at least at the time points analyzed here.
Altogether, these data show that activation of the M2
response in the striatum is less efficient when compared
with the frontal cortex in the experimental conditionsutilized. Furthermore, our data show that the response
to icv IL4 is gene-specific, suggesting that Fizz1 is a more
reliable and targetable marker of IL4-induced activation in
the brain.
Differences in IL4-induced M2 protein expression within
brain regions and cells
We next analyzed whether IL4 activity in the brain
correlated with an increase in M2 protein levels and
whether the temporal profile of protein expression
AD
B
C
Figure 3 Gene expression of M2a, M2c, and M1 polarization markers. Expression of CD206 (A), TGFβ (B), IL1β (C) and TNFα (D) genes was
analyzed by real time PCR on RNA extracted from the frontal cortex (Fr cortex) and striatum of mice treated by intracerebroventricular injection for 16
and 48 h with saline (veh, open bars) or IL4 (black bars), as indicated. Data sets for each gene were calculated with the 2-ddCt method with respect to
the mean value of each vehicle group. Bars represent mean values ± SEM. * P < 0.05 versus veh 16 h; bb P < 0.05 versus striatum 16 h (n = 4 to 6).
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Figure 4 Time course of IL4-induced M2a protein expression in
mouse brain. After intracerebroventricular injection of saline (Veh,
open bars) or IL4 (black bars), the striatum and frontal cortex (Fr.
cortex) were extracted at 16 and 48 h intervals and analyzed by
Western blotting to evaluate Ym1 (A,B) and CD206 (C,D) protein
levels. (A,C) Immunoblots using Ym1, CD206, and β-actin antibodies
from representative samples are shown. The average densitometric
value of the Ym1 (B) and CD206 (D) bands from Western blots of
several samples was normalized to that of β-actin; bars represent
mean values ± SEM; the arbitrary value of 1 was given to the value
of the saline 16 h group for each protein and brain area analyzed
(n = 4 to 6). BMDM, bone-marrow-derived macrophages.
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M2 genes. To this aim, M2 protein levels were evaluated
by Western blot analyses in the striatum and frontal
cortex of mice injected with IL4; we were unable to assay
Fizz1 and Arg1 proteins, owing to low specificity of the
antibodies tested. As shown in Figure 4, a three-fold
induction of Ym1 protein is observed in the striatum after
16 h, while Ym1 expression is similar to basal levels after
48 h treatment with IL4; on the contrary, 4.5 and 8-fold
increases in Ym1 levels were observed in the frontal
cortex after 16 and 48 h treatment, respectively, substanti-
ating the diversity of the IL4 response in the two brain
regions analyzed. In vehicle-treated mice, Ym1 protein
levels (as well as mRNA levels; data not shown) were simi-
lar to those obtained in intact mice, with fold induction in
protein expression values being 2.2 and 0.9 in the striatum
and 0.8 and 0.9 in the frontal cortex at 16 and 48 h,
respectively (data not shown), indicating that icv injection
per se does not alter Ym1 expression, at least in the
experimental condition assayed. The potency of the IL4
induction of Ym1 protein is in agreement with that related
with Ym1 mRNA levels, which are shown in Figure 1C; in
fact, similar induction levels of Ym1 protein are observed
in the striatum and correlate with the lack of mRNA
induction in this area following 30 and 48 h treatment
(Figures 1C, 4B), whereas in the frontal cortex the persist-
ence of Ym1 mRNA induction at 30 h correlates with
the Ym1 protein increase assessed 48 h after treatment
(Figures 1C, 4B). Thus, these results show that induction
of Ym1 protein is more pronounced and persistent in the
frontal cortex than in the striatum.
Importantly, the induction of CD206 protein by IL4
is also restricted to the frontal cortex, with no effect
occurring in the striatum (see Figure 4C,D). The spe-
cificity of the CD206 protein signal is confirmed by
loading protein extracts from vehicle- and IL4-treated
bone-marrow-derived macrophage cells aside brain
samples. Such a region-specific induction of CD206 to
IL4 is consistent with the respective temporal profile
of CD206 mRNA level induction in these areas (see
Figure 3A). Thus, these data extend the assessment of
the M2a activation profile induced by IL4 in brain
Pepe et al. Journal of Neuroinflammation  (2014) 11:211 Page 10 of 14and sustain the novel concept of the region-specific
diversity in microglia polarization.
To evaluate whether the difference in the M2 response
between the striatum and frontal cortex could be ascribed
to an altered expression of IL4 receptor α (IL4Rα), mRNA
levels of IL4Rα were evaluated in the striatum and frontal
cortex of control and IL4-treated mice following 48 h
treatment. Similar levels of IL4Rα mRNA were detected in
these experimental groups (see Additional file 1), suggest-
ing that the different M2 response to IL4 in the striatum
and frontal cortex cannot be ascribed to a difference in
IL4Rα expression.
Altogether, the difference in the Ym1 and CD206
levels between the striatum and frontal cortex demon-
strates a region-specific difference in M2 polarization in
response to IL4.IL4-induced M2 response is triggered by microglia cells
We then asked whether the observed induction of M2 gene
expression by icv IL4 could be ascribed specifically to
microglia. Double-labeling immunohistochemistry was used
to localize Ym1 protein expression within specific brain cell
types using antibodies against cell type-specific proteins,
such as Mac-1, NeuN, and GFAP, known to be exclusivelyFigure 5 Microglial localization and distribution of Ym1 protein in br
vehicle (A,D,F) and IL4 (B,C,E,G) were analyzed by co-immunostaining usin
specific antibodies Mac-1 (A-C), NeuN (D-E), and GFAP (F,G), revealed in g
striatum (C). The Ym1 signal specifically co-localized with Mac-1-positive ce
and C. Bar, 30 μm; dashed bar, 8 μm.expressed by microglia, neurons, and astrocytes, respect-
ively, each one was assayed together with an antibody
against Ym1. As expected, the Ym1 signal was detected in
microglial cells of the frontal cortex and striatum following
16 h of IL4 treatment, as shown in Figure 5A-C, with no
evident morphological changes induced by IL4 in microglia
cells. Conversely, we did not find any co-localization
between Ym1 and neuronal or astrocytic markers (see
Figure 5D-G). Interestingly, not all Mac-1-positive micro-
glial cells display Ym1 expression following IL4 treatment;
in fact, we estimated Ym1 responder cells being about 25
and 18% of the total number of Mac-1-positive microglia in
the frontal cortex and striatum, respectively (data not
shown) suggesting that a subpopulation of resident
microglia corresponds to IL4-responding cells. Of notice,
Ym1-positive microglia cells were preferably, although not
exclusively, in close proximity to each other (see Figure 5B).
Altogether, these results suggest that the brain M2 response
to IL4 can be ascribed solely to a subset of microglia cells.IL4-induced M2 response is triggered by a subset of
microglia cells
To assess more precisely the percentage of IL4 responsive
microglia cells, fluorescence-activated cell sorting analysesain cells. Brains after 16 h intracerebroventricular treatment with
g Ym1 antibody (A-G), here observed as red signals, together with cell
reen. Images were taken in the frontal cortex (Fr. cortex, A,B,D-G) or
lls, highlighted by white arrows and higher magnification inserts in B
Pepe et al. Journal of Neuroinflammation  (2014) 11:211 Page 11 of 14were performed on microglia purified from the cortex of
adult mice 16 h after icv IL4 injection. Data show that the
dissociated brain cells population before immunosorting
contains CD11b-positive microglia that are about 12% of
the total cell number and show a specific morphological
and scattering profile, as expected (see Figure 6A).
Magnetic beads loaded with anti-CD11b antibody
allow sorting of a 90 to 95% pure microglia cell
population (data not shown). Most importantly, staining
with anti-Ym1 antibody on immunosorted microglia from
saline or IL4 injected animals demonstrate that the
Ym1 signal is only detected in a subset of microglia
cells, as shown in Figure 6B. The average number of
Ym1 responder cells after IL4 treatment is about 25%
of the total microglia cells (see Figure 6C). Thus, these
results further demonstrate the existence of a subpopulation
of Ym1 responder microglia that undergoes polarization in
response to IL4 in vivo.
To extend our observation on the existence of subsets
of IL4 responsive microglia, we analyzed the percentageGate 1
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Figure 6 Ym1 responder microglia subset. Microglia cells were extracte
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protein expression. (A) CD11b-positive cells were characterized before purifica
other brain cells. (B) After immunosorting, IL4 treatment is ineffective in induc
Conversely, IL4 induces an increase in Ym1 expression in CD11b-positive cells
microglia cells shows that a significant percentage of cells (≈25%) is inducedof microglia expressing Arg1. As shown in Figure 7,
immunohistochemical analysis using paraffin-embedded
brain tissue enabled assessment that Arg1 expression is
detected only after IL4 injection and solely in microglia
cells, further confirming our results on the specificity of
Ym1 expression in microglia. Most interestingly, by count-
ing the number of Arg1-positive microglia cells and the
total number of Iba1-positive microglia cells, we observed
that a 35% subset of microglia cells is Arg1 responder
microglia. In addition, these data also show that the
percentage of IL4 responsive microglia may vary slightly,
depending on the M2 marker analyzed.
Altogether these results demonstrate that the M2
polarization induced by IL4 in brain can be ascribed
specifically to a subset microglia cells.
Discussion
The aim of this study was to evaluate the extent to
which microglia undergo M2 polarization in vivo. We
thus developed a method that makes use of centrallyC
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d from the cortices of mice treated for 16 h intracerebroventricularly
tic beads and analyzed by fluorescence-activated cell sorting for Ym1
tion and show a specific forward and side scatter profile with respect to
ing Ym1 expression in the microglia-depleted fraction (upper panel).
(lower panel). (C) Quantitative analysis of the number of Ym1-positive
by the IL4 treatment. *: P < 0.05; n = 3.
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Figure 7 Selective induction of Arg1 expression in a subset of
microglia. Brains after 16 h intracerebroventricular treatment with
vehicle (A,C) and IL4 (B,D) were formalin fixed and embedded in
paraffin and analyzed by immunohistochemistry to visualize Iba1 (A,B)
or Arg1 (C,D) in the frontal cortex. Arg1 expression is observed
selectively in microglia-like cells after IL4 treatment and is restricted to a
subset of cells (D). Scale bar 100 μm. The results obtained by counting
the number of Arg1-positive microglia cells and the total number of
Iba1-positive microglia cells demonstrated that an≈ 35% subset of
microglia cells is Arg1 responder microglia (E). Veh., vehicle.
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This experimental model allowed us to estimate the
different ability of microglia populating the striatum
and cerebral cortex to induce M2a gene expression and to
identify the existence of subpopulations of microglia that
support the IL4 response in brain.
Phenotype and functional plasticity is a characteristic
of microglia; the presence of M1 and M2 phenotypes and
a wide spectrum of intermediate and concomitant activa-
tion programs has been documented in animal models of
cerebral diseases although with different ratios, temporal
involvement and functional outcomes [23,24,27-30].
Activation of the brain M2 phenotype has been previously
observed in animal models of neurological diseases and
associated with suppression of inflammation, tissue
remodeling and matrix deposition in a time- and
environment-specific manner [23,24,27-30]. It is believed
that M1 activation, that is, a protective innate immune
response per se, might be exaggerated or unrestrained as a
consequence of both acute CNS damage, such as
after traumatic and ischemic reperfusion injuries, or
under chronic neuroinflammation, as in Parkinson’sand Alzheimer’s diseases or multiple sclerosis; under
these pathologic conditions several studies have shown that
the anti-inflammatory and reparative response driven by
alternative microglia polarization is dampened, as a conse-
quence of the increased, self-propagating proinflammatory
phenotype, revealing that the loss of an appropriate M2
response harms the dynamic and heterogeneous nature of
microglia response and thus contributes to neurodegenera-
tion [19]. However, the overall contribution of this response
to neuroprotection and its specific involvement in prevent-
ing the development of neuropathological lesions within
specific brain regions are still poorly understood.
Intriguingly, our data show that the M2a response in
the striatum is less efficient than that observed in frontal
cortex, in terms of M2a gene expression both at the
mRNA and protein levels (see Figures 1, 2 and 4). One
could thus hypothesize that microglia M2a response,
being limited or inefficient within the nigrostriatal
pathway, might be defective in the mechanisms that lead
to reduction of neurotoxicity and to tissue repair and
might thus contribute to the increased vulnerability of
this neuronal population to neuroinflammation [2,20].
Indeed, neurotoxicity induced by the microglial M1
phenotype within the nigrostriatal pathway is further
regulated by local cues, as demonstrated by dopamin-
ergic neurons, which were shown to potentiate neuro-
toxicity under inflammatory pathologic conditions by
oxidative dopamine metabolism. Dopaminergic neurons
massively die in response to microglia M1 activation,
whereas other neuronal populations involved in Parkinson’s
disease etiopathogenesis survive the neuroinflammatory
insult [8,16,31-33]. Our demonstration of a heterogeneous
microglia M2a response lends further support to the
hypothesis that region-specific responsiveness of microglia
might be involved in the increased neuronal susceptibility
to neuroinflammation.
Besides the nature, intensity, and persistency of the
trigger, the responsiveness of microglia at a given time
and within a specific anatomical location plays a central
role in neuroinflammation. Activation of a specific pheno-
type is dictated by the number of responsive microglia
and the ability of these responder cells to undergo
polarization; it is believed that such properties are
influenced by the specific environment in which
microglia reside [2,9]. Adding complexity to this view,
recent evidence supports the existence of subtypes of
responder microglia within the same anatomical location,
which are instructed by as yet undefined local signals to
execute specific tasks that concur in housekeeping and
inducible functions, such as immunological, clearing, and
inflammatory actions [13-15]. In this scenario, our immu-
nohistochemistry data provide a demonstration that the
M2a response is specifically assigned to a subpopulation
of microglia cells (see Figures 6 and 7). Although IL4 has
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responses [34], our data suggest that the subset of
microglia that triggers the M2a response represents
a specific cellular target for improving regeneration
and reducing proinflammatory neurotoxicity. Future
investigations will therefore be relevant not only for
understanding the physiology of these cells, but also
for gaining insight into the biochemical pathways
that govern the reactive potential of resident micro-
glia subtypes. This information will allow the identi-
fication of novel therapeutic agents that increase
neuron survival by targeting microglia reactivity [19]
as well as the development of novel tracers that
enable the functional imaging of the M2 phenotype
in live animals [35].
In this perspective, icv IL4 administration represents a
valuable experimental procedure to study the signaling
pathways that control microglia M2 polarization. The
use of this experimental model allows induction of
the M2a response all over the brain, with no signs of
inflammatory reactions in vehicle-treated subjects.
Along with distribution, the rapidity, potency, and
persistency of the M2a response observed following
central administration of IL4 represent advantageous
features in estimating the capability of microglia cells
to acquire the M2a phenotype among and within dif-
ferent brain areas, in physiological as well as patho-
logical conditions. Among the genes analyzed, Fizz1
reached the highest induction levels in both the stri-
atum and the frontal cortex. Expression of all M2a
genes analyzed in this study has been shown to be
dependent upon the IL4 signaling and coordinate
action of IL4-inducible transcription factors [36-38];
yet, our data show that the IL4 signaling pathway that
converges on Fizz1 expression in the brain is highly
efficient and, although its role in neuroinflammation
is not clear [39,40], suggest that Fizz1 may be considered
as a reliable marker of IL4-induced M2a activation
in brain.
Conclusions
The results presented here show that central administra-
tion of IL4 induces a specific temporal pattern of M2a
gene expression in striatum and frontal cortex, with
Fizz1 being the most inducible gene among those tested.
Our results show that the responsiveness of brain mac-
rophages to centrally administered IL4 might change
among brain areas and that microglia M2a polarization
can be ascribed to a subpopulation of IL4 responsive
cells. Therefore, the biochemical pathways that instruct
and enable microglia to undergo M2a activation represent
key aspects in the physiopathology of microglia and
challenging opportunities for the development of novel
therapeutic and diagnostic agents.Additional file
Additional file 1: IL4Rα expression in the mouse brain. The mRNA
levels of IL4Rα were analyzed by real time PCR on the striatum and
frontal cortex (fr. cortex) of control (Veh) and IL4-treated mice following
48 h treatment. Data are reported as ΔCt (dct) values with respect to the
36B4 housekeeping gene (n = 4).
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